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Abstract
Aims/hypothesis The success of islet transplantation as a
treatment for type 1 diabetes is currently hampered by
post-transplantation loss of functional islets through adverse
immune and non-immune reactions. We aimed to test
whether early islet loss can be limited and transplant survival
improved by the application of conformal nano-coating layers
to islets.
Methods Our novel coating protocol used alternate layers of
phosphorylcholine-derived polysaccharides (chitosan or
chondroitin-4-sulphate) and alginate as coating materials,
with the binding based on electrostatic complexation. The
in vitro function of encapsulated mouse islets was studied
by analysing islet secretory function and cell viability. The
in vivo function was evaluated using syngeneic and allogeneic
transplantation in the streptozotocin-induced mouse model of
diabetes.
Results Nano-scale encapsulated islets retained appropriate
islet secretory function in vitro and were less susceptible to
complement- and cytokine-induced apoptosis than non-
encapsulated control islets. In in vivo experiments using a
syngeneic mouse transplantation model, no deleterious
responses to the coatings were observed in host animals,
and the encapsulated islet grafts were effective in reversing
hyperglycaemia. Allo-transplantation of the nano-coated
islets resulted in preserved islet function post-implantation
in five of seven mice throughout the 1 month monitoring
period.
Conclusions/interpretation Nano-scale encapsulation offers
localised immune protection for implanted islets, and may
be able to limit early allograft loss and extend survival of
transplanted islets. This versatile coating scheme has the po-
tential to be integrated with tolerance induction mechanisms,
thereby achieving long-term success in islet transplantation.
Keywords Allogeneic transplantation . Graft survival .
Immunoisolation . Islet transplantation . Nano-coating .
Nano-scale encapsulation . Type 1 diabetes
Abbreviations
HBSS Hanks’ buffered salt solution
PC Phosphorylcholine
PEG Polyethylene-glycol
TEM Transmission electron microscopy
Introduction
Islet transplantation is arguably one of the most important
conceptual advances in the treatment of type 1 diabetes and
has the potential to cure the disease [1]. A major barrier to
successful transplantation is early post-transplantation deple-
tion of functional islets in response to activated complement
and coagulation systems, and to a chronic inflammatory and
immunogenic environment [2–5]. This has obvious detrimen-
tal effects on the outcome of individual grafts and further
exacerbates the scarcity of donor tissue. Moreover, allogeneic
transplantation requires pharmacological suppression of the
host immune system to circumvent graft rejection, while
current immunosuppressive regimens are likely to contribute
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to the early loss of engrafted islets [6]. A strategy that conceals
implanted islets from the host immune system may help to
minimise or even prevent the post-transplantation loss of islet
mass and function by immune rejection. Thus physical isola-
tion of islets from the host environment by encapsulation,
while maintaining islet responsiveness to metabolic changes,
could be an effective means of improving islet survival and
function after transplantation.
Islet encapsulation strategies to date have mainly focused
on macrocapsules (encapsulation of the whole islet graft)
and microcapsules (encapsulation of individual islets) [7].
Previous studies in animal models [8, 9] and in human
participants [10, 11] have demonstrated that physical isola-
tion of islets from the host immune system by, for example,
alginate microencapsulation is effective in preventing beta
cell loss and in maintaining long-term secretory function in
transplanted allogeneic and xenogeneic islets without sys-
temic immunosuppression [12–16]. Although conferring the
immunological advantages predicted from graft/host isola-
tion, microcapsules have some significant drawbacks. Thus
the relatively large volume of a typical alginate capsule
(diameter ∼500–800 μm) compared with a typical islet
(∼150 μm) results in a greatly increased diffusion length,
which can lead to impaired diffusion of oxygen and
nutrients to the islet, with consequent hypoxic cell death or
malfunction. A more immediate consequence of the size of
microcapsules is the choice of anatomical location for the
graft material, with most experimental studies focussing on
intraperitoneal or subcutaneous compartments due to their
large capacity [17]. In contrast, intraportal infusion is the
current site of choice for clinical programmes [1], with the
transplanted islets lodging in the hepatic microcirculation.
An encapsulation technology designed for application to
current clinical transplantation of human islets must there-
fore be compatible with intraportal delivery to the hepatic
capillary bed, excluding microcapsules or macrocapsules on
the basis of their size.
Conformal nano-coating avoids these problems by gen-
erating a biocompatible nanometre-scale isolating layer
close to the cell surface, thus reducing barriers to diffusion,
while ensuring that the encapsulated islets can be implanted
into any site suitable for non-encapsulated islets [7]. The
challenge with conformal nano-coating is to nano-engineer
an efficient and lasting immune-protective layer that covers
islets completely or nearly completely, and is biocompatible
with the recipient.
Several methods of conformal coating have been devel-
oped recently, including covalent surface attachment of
polyethylene glycol (PEG), known as ‘PEGylation’ [18],
and layer-by-layer encapsulation [19–28]. Nano-layers with
different combinations of components, including streptavidin
and biotin–PEG derivatives [19, 24], complement receptor 1
and heparin [25], and PEG–lipid and poly(vinyl alcohol)
[26, 27], have been previously researched as islet surface
coatings. Most of these attempts at islet encapsulation have
focused on development of the method, with relatively little
emphasis on in vivo evaluation of the technology, and partic-
ularly on the maintenance of functional beta cells in an allo-
geneic environment. Teramura and Iwata demonstrated that
coating of islet surfaces with PEG-lipid and urokinase could
effectively protect against blood-mediated inflammatory reac-
tions in a syngeneic mouse model of transplantation [23].
However, a recent study using conformal coating to encapsu-
late islets via layer-by-layer deposition of poly(L-lysine)-g-
PEG-(biotin) and streptavidin failed to show any improve-
ment in the survival and function of the implanted allo-islets
[19]. Effective immunoprotection using nano-coating thus
remains a challenge in islet transplantation.
Layer-by-layer nanofilm deposition has been studied ex-
tensively in connection with the coating of biodevices such
as implants in biomedical applications [29, 30]. In the cur-
rent study, we aimed to adapt this technology to produce a
conformal nano-coating for islets, which covers individual
islets in nano-layers that possess anti-coagulation and anti-
inflammatory properties [31, 32], thus achieving effective
encapsulation without significantly increasing the size of the
islet. Charged linear polysaccharides carrying phosphoryl-
choline (PC) modification were used as coating materials
(Fig. 1), with the binding being based on electrostatic inter-
actions. As demonstrated previously [33], layer-by-layer
deposition of alginate–chitosan nano-layers provides a mild
process (near physiological conditions) that does not in-
volve covalent cross-linking, it is therefore able to leave
the cell surfaces and cell interior undisturbed. In this study,
we investigated the localised immune protective effects of
biopolymer nano-coating of islets and tested whether nano-
scale encapsulation improves early outcomes from syngeneic
and allogeneic islet transplantation in the commonly used
streptozotocin-induced mouse model of type 1 diabetes.
Methods
A more detailed description of research design and methods,
including regents and materials, is available in the electronic
supplementary material (ESM Methods).
Experimental animals For syngeneic transplantation, male
C57BL/6 mice aged 8 weeks and weighing 20–25 g
(Charles River, Margate, UK) were used as donors and
recipients of grafts. For allogeneic transplantation, male
C57BL/6 mice were used as islet graft recipients and Balb/
c mice as tissue donors. Recipient mice were made diabetic
by a single i.p. streptozotocin injection (180 mg/kg; Sigma-
Aldrich, Poole, UK) 5–6 days prior to transplantation and
those with a non-fasting blood glucose concentration of
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≥20 mmol/l were used as recipients. All animal procedures
were approved by our institution’s Ethics Committee and
carried out under licence, in accordance with the UK Home
Office Animals (Scientific Procedures) Act 1986.
Islet isolation Islets were isolated from mice by injecting
collagenase (type XI, 1 mg/ml; Sigma-Aldrich) into the
pancreas via the common bile duct, followed by digestion
for 10 min at 37°C. The islets were purified by centrifugation
(3,500 rpm, 25 min; Universal 320R, Hettich Zentrifugen,
Tuttingen, Germany) in a density gradient (Histopaque-
1077; Sigma-Aldrich). Before being used for encapsulation,
the purified islets were incubated for 16 h in RPMI-1640
medium (Sigma-Aldrich) that was supplemented with 10%
fetal bovine serum, 100 U/ml penicillin and 0.1 mg/ml
streptomycin.
Nano-coating of islets The working solutions of the polysac-
charides, including PC-chitosan, alginate and PC-modified
chondroitin-4-sulphate (1 mg/ml; Fig. 1), were prepared by
dissolving the solids in Hanks’ buffered salt solution (HBSS;
PAA Laboratories, Pasching, Austria), which was pH-
adjusted to 6.9–7.0 and supplemented by 2 mmol/l CaCl2.
Positively charged chitosan-PC and negatively charged algi-
nate (unmodified) were alternately deposited into a multilayer
film on individual islets in suspension in a 1.5 ml Eppendorf
tube. Cationic chitosan-PC (400 μl) was added first to a
suspension of the islets (pre-washed with HBSS) to form a
seeding layer. After 5 min deposition time, two intermediate
washings with the buffer were made using gravity sedimen-
tation for 1 to 2 min to remove any excess, unadsorbed
chitosan-PC. Subsequently, anionic alginate (400 μl) was
adsorbed in the same manner. This process was repeated n
times per batch of islets according to the following layering
scheme: islets/(chitosan-PC–alginate layers)n, where n repre-
sents the number of bilayers. Finally, a PC-modified
chondroitin-4-sulphate (400 μl) layer was added as the outer-
most layer in the same manner as for alginate. Some loss of
islets was incurred, totalling <10% for a typical eight-layer
coating process. All encapsulation solutions were filtered
through a sterile 0.2 μm membrane filter cartridge. All
coating, washing and sample solutions were kept on ice dur-
ing the coating process.
Dynamic insulin secretion from the encapsulated islets En-
capsulated islets were incubated for 16 h (37°C) before
perifusion. The rate and patterns of in vitro insulin secretion
from encapsulated and control islets were assessed using a
temperature-controlled (37°C) multi-channel perifusion sys-
tem, as described previously [34]. Briefly, 40 islets were
loaded on to nylon filters in Swinnex filter holders (Millipore,
Cork, Ireland) and perifused with a bicarbonate-buffered
physiological salt solution (Gey& Gey buffer, made in house)
supplemented by 2 mmol/l CaCl2, 0.5 mg/ml bovine serum
albumin and a concentration of glucose as indicated below.
Fractions were collected every 2 min during (1) a 10 min
perifusion period with buffer containing 2 mmol/l glucose, (2)
a 20 min perifusion with 20 mmol/l glucose and (3) an
additional 20 min perifusion with 2 mmol/l glucose. Insulin
content was assessed by radioimmunoassay [34].
Transplantation of encapsulated islets in diabetic mice Mice
were anaesthetised by inhalation of isoflurane and trans-
planted with 300 islets under the kidney capsule, according
to a procedure reported previously [35]. Briefly, a lumbar
incision was made, the kidney exposed and an incision
made in the capsule. Encapsulated and control islets that
had been centrifuged into pellets in PE50 polyethylene
tubing (Becton Dickinson, Franklin Lakes, NJ, USA) were
placed underneath the kidney capsule using a Hamilton
syringe (Fisher, Two Rivers, WI, USA). All islets were trans-
planted with a delay of no more than 2 h after encapsulation.
In vivo function of islet graft The body weight and blood
glucose concentrations of recipient mice were monitored
every 1–2 days. Reversal of hyperglycaemia was defined
as non-fasting blood glucose concentrations ≤11.1 mmol/l on
at least two consecutive readings. In cured animals, we
assessed the in vivo function of the transplanted islets by an
intraperitoneal glucose tolerance test at 1 month after trans-
plantation. Weight-matched, non-diabetic, non-transplanted
male C57BL/6 mice were used as controls. Fasting blood
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Fig. 1 Chemical structure of the PC moiety-functionalised polysaccharides used in the nano-scale encapsulation. (a) PC-modified (40% of the amine
groups) chitosan (protonated); (b) PC-modified (100% of the carboxylic group) chondroitin-4-sulphate (deprotonated); and (c) PC
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glucose concentrations weremeasured prior to an i.p. injection
of 2 g/kg of glucose dissolved in saline solution and then after
15, 30, 60, 90 and 120 min. The islet graft-bearing kidneys
were removed 1 or 2 days later to assess whether graft removal
would result in a reversion to hyperglycaemia. Other mice in
which the graft was rejected in less than 28 days were killed
and the graft-bearing kidney removed for histological
analysis.
Immunohistochemistry Detailed descriptions of histological
and immunohistological analysis of the graft-bearing
kidneys is available in the ESM Methods.
Statistical analysis Independent t tests were used to test for
significant difference between individual groups of the cy-
tokine assay results and glucose tolerance data. Values of p<
0.05 were considered significant.
Results
Deposition of coating layers on islets We used a nano-scale
encapsulation approach that uses spontaneous deposition
of alternate layers of charged linear polysaccharides (PC-
chitosan/alginate) as coating materials, with a final layer of
PC-modified chondroitin-4-sulphate, as illustrated in Fig. 2.
The nano-coated C57BL/6 mouse islets showed better phys-
ical strength than the uncoated ones, as evidenced by an
increase of 20–30% in packed tissue volume for the same
amounts of islets when loaded in PE50 polyethylene trans-
plantation tubing.
The deposition of eight layers was assessed by fluores-
cence microscopy following the incorporation of two layers
of PC-chitosan tagged with FITC in the fifth and seventh
layers. As shown in Fig. 3a, the addition of the FITC-tagged
layer to the islets resulted in strong fluorescence localised on
the surface of the islets, which is consistent with their
extracellular architecture and indicates uniform coverage.
A few bright spots found on the surfaces of islets may have
been due to the higher surface charges that can occur on cell
or extracellular surfaces. The above image (Fig. 3a) was
taken shortly after encapsulation; however, the coating was
found to be stable in culture throughout 10 days of monitoring
(ESM Fig. 1). Due to the instability of FITC under paraffin-
embedding conditions, we also generated fluorescence-
labelled islets by incorporating poly-L-lysine tagged with
Alexa Fluor 647 in the seventh layer as a fluorescent marker
(see ESMMethods) (Fig. 3b). The cross-section of the labelled
islet showed that the exterior islet surfaces were completely
covered and that the coating was localised extracellularly
(Fig. 3c). Note that the thickness of the fluorescent layer ring
could have been affected by the surface roughness of the islet
and the position of the section taken from the islet.
The deposition of the non-labelled polysaccharide multi-
layers on the individual islets was further confirmed by
high-resolution transmission electron microscopy (TEM)
imaging of the encapsulated islets (Fig. 3d; ESM Methods).
The ultrastructural image showed an intact coating consist-
ing of nano-layers of approximately 80 nm thickness that
covered the outer surface of cells on the islet periphery. The
nano-layer was not found in the extracellular space between
the islet cells. Insulin-secreting vesicles (dense-core gran-
ules) were seen by TEM to be aligned along the plasma
membrane ready for exocytosis, suggesting that beta cells
were healthy and unaffected by the coating.
Deposit
polysaccharide
multilayers
Cell surfaceCell surface
Fig. 2 Schematic representation of the nano-scale encapsulation of
pancreatic islets, with layer-by-layer deposition of charged polysac-
charide multilayers on individual islet surfaces. Blue lines with +
symbol, chitosan-PC; red lines with − symbol, alginate; green lines
with − symbol, chondroitin-4-sulphate-PC
b
c
Nanocoating
Insulin
granule
d
a
Fig. 3 Confirmation of the nano-scale encapsulation of mouse islets.
a Deposition of eight layers with incorporation of two layers of PC-
chitosan tagged with FITC into the fifth and seventh layers. Scale bar
50 μm. b Fluorescence labelling of islets by incorporation of Alexa
Fluor 647-tagged poly-L-lysine into the seventh layer as a fluorescent
marker. Scale bar 100 μm. c Cross-section of a coated islet with an
incorporated layer of Alexa Fluor 647-tagged poly-L-lysine (formalin-
fixed and paraffin-embedded), showing that the nano-layer appears to
completely cover the islet surface. Scale bar 50 μm. d TEM micro-
graph of the cross-section of an islet encapsulated by an eight-layer
coating (consisting of PC-chitosan, alginate and condroitin-4-sulphate
as described in Methods, non-labelled). Islets were imaged shortly after
completion of coating. Scale bar 100 nm
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In vitro cytotoxicity exerted by the coating materials After
maintenance in culture for up to 4 weeks, the survival of
encapsulated mouse islet cells within eight layers was
assessed using a two-colour fluorescence live–dead cell
assay with the cell-permeable esterase substrate, fluorescein
diacetate, and the cell-impermeant nucleic acid stain, propi-
dium iodide (ESM Methods). Most of the cells in the islet
were viable after 1 and 4 weeks of culturing, indicating that
islets tolerated the multi-step nano-coating process with no
or little detectable loss in cell viability (Fig. 4a, b).
In addition, no elevated level of apoptosis in the nano-
coated islets was detected after 48 h in culture compared
with non-encapsulated islets, as shown in Fig. 4c (see ESM
Methods). The rate of islet cell apoptosis (determined as
caspase-3/7 activity) in control islets was increased by ap-
proximately 620% following exposure to combined cytokines
(IL-1β 1.7 ng/ml, TNF-α 1.7 ng/ml and IFN-γ 3 ng/ml), but
this was significantly less in the nano-coated islets. The neg-
ative coating layer with alginate was more potent in inhibiting
cytokine-induced cell damage than chondroitin-4-sulphate-
PC. Nano-coated islets were also protected against apoptosis
mediated by complement (50% rabbit serum; Fig. 4d).
Chondroitin-4-sulphate-PC, an anti-coagulatory molecule
[31, 32], was found to provide a better protective effect than
alginate. Based on the findings above, the coating scheme
adopted for our in vivo experiments used chitosan-PC and
alginate in repeated layers, with the last layer being
chondroitin-4-sulphate-PC.
Assessment of the in vitro function of nano-scale encapsulated
islets Dynamic insulin secretion of the encapsulated islets
was studied and compared with control using a perifusion
system that simulates physiological conditions. As shown in
Fig. 5, the four-layer encapsulated mouse islets retained
glucose-induced insulin secretory responses. Increasing the
glucose concentration from 2 to 20 mmol/l induced a rapid,
biphasic and reversible stimulation of insulin secretion from
islets encapsulated with four layers, with identical or similar
response patterns from control islets. Increasing the nano-
film thickness to eight layers caused a small reduction in the
kinetics and overall amount of insulin released, but the
pattern and reversibility of the glucose-induced response
were maintained.
In vivo assessment of nano-scale encapsulated islet function:
syngeneic transplantation Figure 6a shows the data from
islet transplantation under the kidney capsule from
C57BL/6 donor mice (300 islets/graft) to diabetic recipients
of the same strain. As expected, implantation of non-
encapsulated islets as a control reversed hyperglycaemia
and restored normoglycaemia for the duration of the study
(4 weeks). Nano-scale encapsulated islets with four layers
were equally effective in reversing hyperglycaemia, with a
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Fig. 4 Live–dead cell staining in coated islets. Nano-coated islets
within eight layers of PC-chitosan and alginate were stained with
fluorescein diacetate (green) and propidium iodide (red), and visualised
(a) after 1 week and (b) at 4 weeks post-encapsulation of maintenance
in culture. Green shows viable and red (dots) non-viable cells/islets.
Similar data on uncoated islets can be found in our previous paper [28].
c Activity of caspase-3 and -7 in the eight-layer-encapsulated and
control (non-encapsulated) islets, with (white bars) and without
(hatched bars) exposure to cytokine combination (IL-1β, TNF-α and
IFN-γ). Data were normalised against the value of control non-coated
islets without cytokines. Ch, PC-chitosan; Alg, alginate; CS,
chondroitin-4-sulphate. d Activity of caspase-3 and -7 in islets as
above (c) after 24 h in culture with 50% rabbit serum. Data were
normalised against the value of control non-coated islets exposed to
the serum. Values (c, d) are mean±SD; n03; *p<0.05 for PC-chitosan/
Alg or PC-chitosan/condroitin-4-sulphate-coated islets vs control islets
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time course similar to that of control islet grafts, in agree-
ment with the functionality displayed in in vitro analyses.
All mice reverted to the hyperglycaemic state on removal of
the graft-bearing kidney (Fig. 6a). Subsequent histological
assessment of graft material retrieved 28 days after implan-
tation showed the presence of insulin-positive islet cell mass
in the graft (Fig. 6b, c). There were no morphological differ-
ences between control and encapsulated islet grafts, with
normal patterns of immunostaining for insulin, and no de-
tectable major T cell (CD3 as the biomarker) and host
macrophage (CD68 as the biomarker) infiltration at the graft
sites (ESM Fig. 2).
In vivo assessment of nano-scale encapsulated islet function:
allogeneic transplantation To assess whether encapsulation
offers effective protection against immune rejection, we also
performed studies using an allogeneic islet transplantation
model, in which 300 Balb/c islets (H-2d) were transplanted
below the kidney capsule of streptozotocin-induced diabetic
C57BL/6 mice (H-2b). Transplanted islets reversed hypergly-
caemia within 2–4 days. Animals implanted with control islets
reverted to hyperglycaemia (blood glucose >11.1 mmol/l)
within 10 to 14 days (median survival time 12 days)
(Fig. 7a), consistent with graft rejection by the host im-
mune system. Subsequent histological analysis of the non-
encapsulated islet graft material revealed complete loss of the
islet mass with little or no immunoreactive insulin being de-
tectable (Fig. 7d). T lymphocytic and macrophage recruitment
at the subcapsular implantation site was observed (ESM
Fig. 3). Islets nano-encapsulated with four layers also reverted
to hyperglycaemia, albeit a few days later (median survival
time 15 days), suggesting that this level of encapsulation was
not sufficient to prevent immune rejection (ESM Fig. 4).
Protection from immune assault was more successful in a
further study, in which we implanted islets coated with eight
layers in the allogeneic model. In this study, the graft material
was retrieved after about 1 month for histological analysis.
Nano-scale encapsulated islets maintained normoglycaemia
for 28–37 days (Fig. 7b) in five of seven mice. Reversion to
hyperglycaemia for mice receiving encapsulated islet trans-
plants was caused by graft-bearing kidney removal. Two mice
receiving the encapsulated islets reverted to hyperglycaemia
in less than 28 days due to rejection.
To determine whether transplanted islets secrete insulin
and maintain glycaemic control in response to increases in
blood glucose levels, we carried out intraperitoneal glucose
tolerance tests at 4 weeks post-transplantation in mice that
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lated) and encapsulated (PC-chitosan, alginate, condroitin-4-sulphate)
Balb/C mouse islets in response to changes in extracellular glucose.
Insulin secretion in response to the glucose challenge as a function of
time was studied in a temperature-controlled cell perifusion system.
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Fig. 6 Syngeneic transplantation of the encapsulated islets. a STZ-
induced hyperglycaemia was reversed by implantation of 300 islets of
either control (black circles) islets or islets encapsulated with four
layers (PC-chitosan, alginate, PC-chitosan, PC-condroitin-4-sulphate)
(black squares). Graft removal (upright arrow) caused reversion to
hyperglycaemia. Values are mean±SEM; n06. b Histological analysis
of recovered representative graft sections (5 μm) of encapsulated and
(c) non-encapsulated (control) islets using insulin immune-staining
(brown). Scale bars 50 μm
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had remained normoglycaemic. Figure 7c shows that the
change in glucose level was similar to that of non-diabetic
mice. Histological analysis of the recovered grafts showed
significant amounts of insulin-positive tissue (Fig. 7e) and
no evidence of infiltration of T cells into the islets, although
a few macrophages were detected (ESM Fig. 3).
Discussion
We describe here a new protocol for nano-scale encapsula-
tion of pancreatic islet cells and for the first time demon-
strate in an animal model improved post-transplant survival
of such coated islet cells in comparison with uncoated islets.
Alternate layers of PC-grafted polysaccharides (chitosan
and chondroitin-4-sulphate) were used with alginate as the
coating materials, with the binding being based on electro-
static complexation. Multilayer film formation is possible
because of charge reversal on the film surface after each
adsorption step. The polysaccharides we used contain at
least one charge in each monosaccharide unit, which serves
as the binding site, offering hundreds of binding sites for
each polysaccharide molecule, thus providing a strong affinity
to the charged cellular surfaces. The rationale for using
these polymers in the layer architecture was based on
our in vitro studies, which identified potential complement-
and inflammation-inhibitory activities of these polysacchar-
ides (Fig. 3c, d). Any success of islet encapsulation in extend-
ing graft survival in this study is likely to be dependent to a
large part on the ability of the nano-coating to control the local
transplant microenvironment and restrict immune cell infiltra-
tion, essentially blocking a variety of protein–protein interac-
tions involved in complement (molecular mass 500 kDa),
macrophage and T cell activation. In this regard, we intro-
duced the protein-repelling zwitterionic PC modification
(Fig. 1) in the coating constructs to minimise interactions
between islets and the environment. The PC moiety, which
is a component of plasma cell membranes, confers hydro-
philicity, haemocompatibility and resistance to non-specific
protein absorption, thus inhibiting the development of fibrosis,
supporting endothelial cell growth [36] and also carrying anti-
coagulatory properties [37, 38], all of which should enhance
islet survival in vivo and encourage host integration. In addi-
tion, the 40% amine group content of the PC modification for
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Fig. 7 Allogeneic transplantation of non-encapsulated (a) and eight-
layer-encapsulated ((PC-chitosan and alginate)3 + PC-chitosan + PC-
condroitin-4-sulphate) (b) Balb/c islets reversed STZ-induced hyper-
glycaemia in diabetic C57BL/6 mice. Blood glucose concentrations of
the individual animals (colour + symbol) are shown. Upright arrows
(b), day of nephrectomy. c Intraperitoneal glucose tolerance tests were
performed 4 weeks post-transplantation on mice with encapsulated
islets (black circles) and on non-diabetic, non-transplanted mice as
controls (black squares). Values (a–c) are mean±SEM; n05; (c) p>
0.05 for each data pair. d Histological analysis (insulin immune-
staining, brown) of recovered representative graft-bearing kidney capsu-
les in control non-encapsulated islets and (e) eight-layer-encapsulated
islets. Scale bars 50 μm
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chitosan increased the solubility of the polysaccharide up to
about 2 mg/ml under physiological pH conditions (pH∼7.0).
Using the layer-by-layer deposition technique, a defined
multilayer coating containing PCmodification could be immo-
bilised on the islet cell surfaces (ESM Fig. 5). The thickness
(80 nm) of a typical eight-layer coating, as measured by TEM,
is consistent with that previously reported with similar polymer
sizes (200 nm with 20 layers) [39]. The addition of a polymer,
chondroitin-4-sulphate, that carried a strongly ionic sulphate
group into the complexation pair confers anti-coagulatory
properties to the coating. It also contributes greatly to the
stability of the layered nanofilm [40], making it a very durable
coating even under harsh physiological conditions.
The nano-scale encapsulated mouse islets were found to
preserve appropriate islet secretory function and survival in
vitro. This indicates that the multilayers of the polysaccharides
were deposited non-covalently on to the cell surfaces without
perturbing cellular physiology or compromising cell survival.
Pro-inflammatory cytokines, including IFN-γ, TNF-α and IL-
1β, are major products of activated effective T cells and
macrophages, and are known to be damaging to pancreatic
islets via apoptosis induction [41]. In this study, we found that
the nano-coating also rendered the islets less susceptible to
cytokine- and complement-induced apoptosis (Fig. 4c, d). In
addition, we found that the PC-displayed nano-coating effec-
tively inhibited specific adsorption of large molecules of the
immune systems (IgG, 150 kDa) on to the islet cell surfaces
(ESM Fig. 6), indicating the effectiveness of the non-fouling
PC-modification of the coating materials.
We used the syngeneic transplantation model to assess the
in vivo secretory functionality of nano-scale encapsulated
mouse islets and their ability to reduce hyperglycaemia and
maintain normoglycaemia thereafter. These studies were used
to avoid any influences of graft-versus-host immune rejection
on islet function, while focusing on how the coating layers
could impact on the immediate inflammatory reaction. Our in
vivo tests using the syngeneic mouse transplantation model
showed no deleterious responses from host animals to the
coating materials, suggesting the materials used for encapsu-
lation are non-toxic. Allo-transplantation studies in present
work have shown that tailored encapsulating layers could
optimise islet function post-implantation, allowing a degree
of protection against inflammation and immune rejection in
the majority of the studies. In the current study, nano-scale
encapsulated islets were responsive to a hyperglycaemic en-
vironment, secreted appropriate amounts of insulin to restore
normoglycaemia and survived for an extended period in vivo.
The failure of encapsulation to prevent rejection in two of
the seven animals studied is of note and may indicate
incomplete coating before transplantation or degradation at
some time after transplantation. Future studies will need to
test whether the robustness or completeness of the coating
can be improved.
Since the purpose of our study was to prevent or reduce
early-stage islet loss, we considered that a 4–5 week post-
transplant observation period was appropriate. The rejection
in controls normally occurs at 10–14 days (Fig. 7a), so the
chosen study period showed that graft survival was twice as
long. We have to look at grafts when the animals are normo-
glycaemic to determine whether there are any signs of graft
destruction or whether the graft has a normal histological
appearance. A long-term study of the function and graft sur-
vival with this multilayer coating scheme has not yet been
performed. Nevertheless, unlike the arguably more expected
durability of alginate microcapsules [15, 42], the nano-layers
used in this study, while being non-biodegradable, are not
expected or intended to last for many months under in vivo
conditions. Rather, we propose that nano-scale encapsulation is
an alternative technology that may promote engraftment by
allowing intraportal administration and by limiting early islet
loss caused by exposure to an inflammatory environment. In
fact, our in vitro cytokine exposure study (Fig. 3c, d) confirmed
that the encapsulation layers were protective against the cyto-
toxic effects of cytokines and complement proteins, as assessed
by a reduction of apoptosis. Thus by the integration of graft
tolerance inductionmechanisms, the encapsulated environment
may promote the development of regulatory T cells, which
inhibit unintended host immune system activation, thereby
achieving permanent survival of the transplanted islets [43, 44].
Studies are now needed to test whether modifications of
the nano-layers will enhance engraftment and prevent rejec-
tion of islets in the longer term. This may involve: (1)
incorporating bioactive molecules such as complement and
coagulation inhibitors into the layers to prevent islet loss
caused by the instant blood-mediated inflammatory reac-
tion; (2) incorporating anti-inflammatory agents to reduce
localised inflammation and fibrosis; or (3) incorporating
natural and/or artificial extracellular matrices to provide
optimal cell functioning after engraftment. Since there is
little or no increase in size and volume of the islets after
encapsulation, we expect this protocol will be potentially
suitable for hepatic implantation via intraportal infusion.
Such an option now needs to undergo experimental testing.
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